Acadia Pharmaceuticals IncACAD
ASignal's systematic analysis rates ACAD as Bullish.
Reflects the latest available analysis · analyzed Aug 20, 2026
The case on ACAD
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong free cash flow generation ($68.65M)
- High gross margin (62.06%) indicating pricing power
- Exceptional return on equity (35.74%)
- Low debt-to-equity ratio (0.06x) signaling strong financial health
- Significant cash reserves ($956.47M) relative to debt ($73.85M)
- Revenue growth of 16.4% YoY, above threshold for high growth
- RSI at 71.13, indicating overbought conditions
- High forward P/E of 34.00x and PEG ratio of 50.86x suggesting overvaluation relative to growth
- No Reddit mentions, indicating lack of retail investor interest or potential visibility risk
- EV/EBITDA elevated at 43.93x, raising valuation concerns
See the full verdict on ACAD
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes ACAD
Most investors never get a second opinion, let alone several. ASignal runs ACAD past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.